London Stock Exchange · Healthcare
Invest in CRISM Therapeutics stock from India
Indian and foreign residents can buy CRISM Therapeutics (CRTX) shares directly through Paasa.
By Paasa · Updated
CRISM Therapeutics at a glance
- Price
- £0.10+£0.00 (0.00%)
- Market cap
- £3.75M
- Day range
- £0.10 – £0.10
- P/E
- -1.96
- Dividend yield
- None
- Volume
- 29.66K
- 1 month
- -15.22%
- 6 months
- -17.02%
- YTD
- -2.50%
- 1 year
- +2.63%
- 5 years
- -15.22%
CRISM Therapeutics statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | £0.0 | £20.0K | £56.9K | £0.0 | £0.0 |
| Gross profit | −£117.0K | £16.8K | −£3.8K | £0.0 | £0.0 |
| Operating income | −£2.1M | −£465.1K | −£216.7K | −£2.2M | −£1.8M |
| Net income | −£1.9M | −£485.0K | −£247.7K | −£2.4M | −£1.5M |
| Earnings per share | −£0.05 | −£0.08 | −£0.03 | −£0.28 | −£0.18 |
| EBITDA | −£2.1M | −£452.3K | −£2.1M | −£1.9M | −£1.8M |
| Total assets | £1.8M | £1.8M | £160.5K | £23.9M | £31.2M |
| Total debt | £0.0 | £0.0 | £496.8K | £0.0 | £0.0 |
| Cash and short-term investments | £1.1M | £1.3M | £1.3K | £2.9M | £4.9M |
| Shareholders' equity | £1.4M | £1.5M | £4.1M | £23.1M | £30.1M |
| Operating cash flow | −£2.0M | −£933.0K | −£2.8M | −£3.4M | −£1.8M |
| Free cash flow | −£2.0M | −£961.0K | −£2.8M | −£3.0M | −£2.3M |
| Capital expenditure | £0.0 | −£28.0K | −£12.0K | −£265.5K | −£426.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in GBP; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Cizzle Biotechnology | CIZ.L | £0.02 | £722.44M |
| Tissue Regenix | TRX.L | £0.07 | £516.45M |
| MyHealthChecked | MHC.L | £0.09 | £455.31M |
| N4 Pharma | N4P.L | £0.00 | £395.33M |
| Proteome Sciences | PRM.L | £0.01 | £382.82M |
| Theracryf | TCF.L | £0.00 | £365.32M |
| Feedback | FDBK.L | £0.06 | £278.22M |
| Oxford BioDynamics | OBD.L | £0.00 | £245.01M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in CRISM Therapeutics from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to GBP when you buy.
Step 3
Search CRTX and buy
Find CRISM Therapeutics by name or by its ticker, CRTX, and place your order.
Why invest in CRISM Therapeutics from India
What CRISM Therapeutics does
CRISM Therapeutics Corporation is dedicated to developing innovative drug delivery systems that enhance the effectiveness of cancer medications targeting solid tumors. Their primary offering, ChemoSeed, is designed for direct insertion into a tumor or the surgical site post-tumor removal, ensuring that therapeutic concentrations of chemotherapy agents are precisely localized to the cancerous tissue. CRISM Therapeutics operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy CRISM Therapeutics stock from India?
Yes. Indian residents and NRIs can buy CRISM Therapeutics (CRTX) shares directly through Paasa. CRISM Therapeutics is listed on the London Stock Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
How are CRISM Therapeutics dividends taxed for Indian investors?
CRISM Therapeutics trades on the London Stock Exchange but is domiciled in British Virgin Islands, so any withholding on its dividends follows that country's rules rather than those of the UK. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell CRISM Therapeutics shares?
Non-residents are exempt from UK capital gains tax on the disposal of listed shares. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the GBP/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
Is there stamp duty when I buy CRISM Therapeutics shares?
The UK charges 0.5% Stamp Duty Reserve Tax when buying direct company shares electronically on the LSE; ETFs and UCITS funds do not attract it.